Media Summary: In the second segment of a debate series, Prospective Trial of Axitinib in I/O - refractory RCC. At the American Society of Clinical Oncology (ASCO) 2012,
In the second segment of a debate series, Prospective Trial of Axitinib in I/O - refractory RCC. At the American Society of Clinical Oncology (ASCO) 2012,
Patient Success Stories: Metastatic
Today's guest is
Updates in
Dr
Brian Rini
In the second segment of a debate series,
In the final segment of a debate series,
Brian
Brian Rini
At the OncoAlert Colloquium 2026,
Our OncoAlert Faculty
Prospective Trial of Axitinib in I/O - refractory RCC.
At the American Society of Clinical Oncology (ASCO) 2012,